These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27144829)

  • 41. Multidrug resistance in glioblastoma stem-like cells: Role of the hypoxic microenvironment and adenosine signaling.
    Uribe D; Torres Á; Rocha JD; Niechi I; Oyarzún C; Sobrevia L; San Martín R; Quezada C
    Mol Aspects Med; 2017 Jun; 55():140-151. PubMed ID: 28223127
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme.
    Garrido W; Rocha JD; Jaramillo C; Fernandez K; Oyarzun C; San Martin R; Quezada C
    Curr Drug Targets; 2014; 15(10):931-42. PubMed ID: 25174341
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salinomycin's potential to eliminate glioblastoma stem cells and treat glioblastoma multiforme (Review).
    Magrath JW; Kim Y
    Int J Oncol; 2017 Sep; 51(3):753-759. PubMed ID: 28766685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glioblastoma cancer stem cell biology: Potential theranostic targets.
    Sharifzad F; Ghavami S; Verdi J; Mardpour S; Mollapour Sisakht M; Azizi Z; Taghikhani A; Łos MJ; Fakharian E; Ebrahimi M; Hamidieh AA
    Drug Resist Updat; 2019 Jan; 42():35-45. PubMed ID: 30877905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular neuro-oncology and the challenge of the blood-brain barrier.
    Aiken R
    Semin Oncol; 2014 Aug; 41(4):438-445. PubMed ID: 25173137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does cilengitide deserve another chance?
    Tucci M; Stucci S; Silvestris F
    Lancet Oncol; 2014 Dec; 15(13):e584-e585. PubMed ID: 25456376
    [No Abstract]   [Full Text] [Related]  

  • 47. MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.
    Wu X; Luo Q; Zhao P; Chang W; Wang Y; Shu T; Ding F; Li B; Liu Z
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2961-2966. PubMed ID: 30718431
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does cilengitide deserve another chance?-Authors' reply.
    Stupp R; Picard M; Weller M
    Lancet Oncol; 2014 Dec; 15(13):e585-e586. PubMed ID: 25456377
    [No Abstract]   [Full Text] [Related]  

  • 49. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.
    Auffinger B; Spencer D; Pytel P; Ahmed AU; Lesniak MS
    Expert Rev Neurother; 2015; 15(7):741-52. PubMed ID: 26027432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug resistance in glioblastoma: a mini review.
    Haar CP; Hebbar P; Wallace GC; Das A; Vandergrift WA; Smith JA; Giglio P; Patel SJ; Ray SK; Banik NL
    Neurochem Res; 2012 Jun; 37(6):1192-200. PubMed ID: 22228201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential therapeutic implications of cancer stem cells in glioblastoma.
    Cheng L; Bao S; Rich JN
    Biochem Pharmacol; 2010 Sep; 80(5):654-65. PubMed ID: 20457135
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge.
    Dasgupta A; McCarty D; Spencer HT
    Biochem Biophys Res Commun; 2010 Jan; 391(1):170-5. PubMed ID: 19903457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic strategies targeting glioblastoma stem cells.
    Carrasco-Garcia E; Sampron N; Aldaz P; Arrizabalaga O; Villanua J; Barrena C; Ruiz I; Arrazola M; Lawrie C; Matheu A
    Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):216-27. PubMed ID: 23607282
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.
    Head RJ; Fay MF; Cosgrove L; Y C Fung K; Rundle-Thiele D; Martin JH
    Cancer Biol Ther; 2017 Dec; 18(12):917-926. PubMed ID: 29020502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.
    Orzan F; De Bacco F; Crisafulli G; Pellegatta S; Mussolin B; Siravegna G; D'Ambrosio A; Comoglio PM; Finocchiaro G; Boccaccio C
    Stem Cells; 2017 Nov; 35(11):2218-2228. PubMed ID: 28895245
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies.
    Balça-Silva J; Matias D; Carmo AD; Sarmento-Ribeiro AB; Lopes MC; Moura-Neto V
    Semin Cancer Biol; 2019 Oct; 58():130-141. PubMed ID: 30266571
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glioblastoma: therapeutic challenges, what lies ahead.
    Lima FR; Kahn SA; Soletti RC; Biasoli D; Alves T; da Fonseca AC; Garcia C; Romão L; Brito J; Holanda-Afonso R; Faria J; Borges H; Moura-Neto V
    Biochim Biophys Acta; 2012 Dec; 1826(2):338-49. PubMed ID: 22677165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA repair and cancer stem-like cells--potential partners in glioma drug resistance?
    Johannessen TC; Bjerkvig R; Tysnes BB
    Cancer Treat Rev; 2008 Oct; 34(6):558-67. PubMed ID: 18501520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The ABCG2 resistance network of glioblastoma.
    Bleau AM; Huse JT; Holland EC
    Cell Cycle; 2009 Sep; 8(18):2936-44. PubMed ID: 19713741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme.
    Arévalo ÁST; Erices JI; Uribe DA; Howden J; Niechi I; Muñoz S; Martín RS; Monrás CAQ
    Curr Med Chem; 2017; 24(25):2781-2795. PubMed ID: 28260500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.